Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle.

Li Zhang,Meser M Ali,Nadimpalli Rs Varma,James R Ewing,Zhang Z Gang,Ali S Arbab

doi:10.4172/2157-7439.1000404

Abstract

There is no available targeted therapy or imaging agent for triple negative breast cancer (TNBC). We developed a small-sized dendrimer-based nanoparticle containing a clinical relevant MRI contrast agent, GdDOTA and a NIR fluorescent dye, DL680. Systemic delivery of dual-modal nanoparticles led to accumulation of the agents in a flank mouse model of TNBC that were detected by both optical and MR imaging. In-vivo fluorescence images, as well as ex-vivo fluorescence images of individual organs, demonstrated that nanoparticles accumulated into tumor selectively. A dual modal strategy resulted in a selective delivery of a small-sized (GdDOTA)42-G4-DL680 dendrimeric agent to TNBC tumors, avoiding other major organs.

Highlights

Breast cancer is the second disease that kills American women than any other malignancy
We studied the in vivo pharmacokinetics and biodistribution for these G3 and generation 5 (G5) dendrimerbased nanoparticles
We demonstrated that a G3-based agent is excreted through kidney [30] while the G5-based agent is excreted through liver [22]

Summary

Introduction

Breast cancer is the second disease that kills American women than any other malignancy. There are approximately 20-30% of breast cancers have shown the overexpressed HER2/nue receptors [1,2]. Having appropriate targets, these patients are treated with endocrine therapy or with anti-HER2 monoclonal antibody, trastuzumab [2]. These patients are treated with endocrine therapy or with anti-HER2 monoclonal antibody, trastuzumab [2] There is another subtype of breast cancer that lacks appropriate targets is known as triple-negative breast cancer (TNBC) [1]. There is no available targeted therapy for these patients and they are dependent on systemic treatment options which are limited to chemotherapy [3]. There is an urgent need to develop better diagnosis and treatment option for TNBC

Methods

Results

Conclusion